PD0166285
CAS No. 185039-89-8
PD0166285( PD0166285 | PD 0166285 | PD0166285 )
Catalog No. M17395 CAS No. 185039-89-8
PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations.PD0166285 is a novel G2 checkpoint abrogator.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 66 | In Stock |
|
| 5MG | 119 | In Stock |
|
| 10MG | 189 | In Stock |
|
| 25MG | 416 | In Stock |
|
| 50MG | 610 | In Stock |
|
| 100MG | 869 | In Stock |
|
| 500MG | 1737 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePD0166285
-
NoteResearch use only, not for human use.
-
Brief DescriptionPD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations.PD0166285 is a novel G2 checkpoint abrogator.
-
DescriptionPD0166285 is a potent Wee1 inhibitor and Chk1 inhibitor with activity at nanomolar concentrations. This G2 checkpoint abrogation by PD0166285 was demonstrated to kill cancer cells, there at a toxic highest dose of 0.5 muM in some cell lines for exposure periods of no longer than 6 hours. The deregulated cell cycle progression may have ultimately damaged the cancer cells. We herein report one of the mechanism by which PD0166285 leads to cell death in the B16 mouse melanoma cell line.
-
In VitroPD0166285 (0.5 μM) dramatically inhibits irradiation-induced Cdc2 phosphorylation at the Tyr-15 and Thr-14 in seven of seven cancer cell lines.PD0166285 sensitizes radiation-induced cell killing in p53 mutant HT29 cells and in the E6-transfected, p53-null ovarian cancer cell line PA-1 but to a lesser extent in p53 wild-type PA-1 cells. PD0166285 abrogates irradiation-induced G2 arrest and significantly increases mitotic cell populations. PD0166285 acts as a radiosensitizer to sensitize cells to radiation-induced cell death with a sensitivity enhancement ratio of 1.23. Western Blot Analysis Cell Line:Human and mouse cancer cell lines (HCT116, HT29, DLD-1, HCT8, H460, HeLa, C 26).Concentration:0.5 μM.Incubation Time:4 h.Result:Inhibited Cdc2Y15 and CdcT14 phosphorylation.
-
In VivoAnimal Model:Wild-type, Abcg2-/-, Abcb1a/b-/- and Abcb1a/b;Abcg2-/- FVB mice.Dosage:5 mg/kg.Administration:IV.Result:Cmax is about 400 ng/mL. P-gp, but not BCRP, limited the brain penetration of PD0166285.
-
SynonymsPD0166285 | PD 0166285 | PD0166285
-
PathwayGPCR/G Protein
-
TargetGPCR19
-
RecptorWee1| Chk1| Myt1
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number185039-89-8
-
Formula Weight512.43
-
Molecular FormulaC26H27Cl2N5O2
-
Purity>98% (HPLC)
-
SolubilityDMSO : 65 mg/mL 126.85 mM; H2O : < 0.1 mg/mL
-
SMILESCCN(CC)CCOc1ccc(Nc2nc3c(cn2)cc(c(=O)n3C)c2c(Cl)cccc2Cl)cc1
-
Chemical Name6-(2,6-dichlorophenyl)-2-((4-(2-(diethylamino)ethoxy)phenyl)amino)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wang Y, etal. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.[J]. Cancer Research, 2001, 61(22):8211-7.
molnova catalog
related products
-
BAR502
BAR502 is a truncated side chain alcohol with both substituents on ring B in α-configuration.
-
SBI-115
SBI-115 is an?antagonist of?TGR5.?SBI-115 decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5.
-
TC-G 1005
TC-G 1005 is a potent and selective GPBA agonist (EC50 :0.72 nM; hTGR5). Selective for TGR5 over FXR (farnesoid X receptor). Increases plasma GLP-1 levels and reduces blood glucose in mice.
Cart
sales@molnova.com